PharmaSources.com MSC Advertisement
Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

12

Apr 2021

Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations

Antengene Corporation Limited a leading innovative biopharmaceutical company dedicated to discovering developing and commercializing global firstinclass andor bestinclass therapeutics in hematology and oncology

12

Apr 2021

HEC Pharm Selects ABEC Large-Scale Fermenters to Increase Biopharmaceutical Production Capacity

ABEC a global provider of integrated solutions and services for biopharmaceutical manufacturing announced it will design manufacture and install multiple L fermenter trains for HEC Pharms manufacturing site in Guangzhou China

09

Apr 2021

Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer

Celcuity Inc a clinicalstage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer today announced it has entered into a global licensing agreement with Pfizer Incgranting Celcuity exclusive rights to Pfizers gedatolisib a Phase...

09

Apr 2021

Context-therapeutics-and-integral-molecular-enter-collaboration-and-license-deal-for-novel-claudin-6-antibodies-for-gynecologic-cancer-therapeutic-program

Context Therapeutics a clinicalstage womens oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormonedriven breast and gynecological cancers

press releasesRead more...

12

Apr 2021

RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue

RedHill Biopharma Ltd a specialty biopharmaceutical company announced that the global Phase study with orallyadministered opaganib Yeliva ABC in patients hospitalized with severe COVID pneumonia has received a unanimous recommendation

11

Apr 2021

GenScript, Parkway Laboratories and Diagnostics Development (DxD) Hub collaborate to provide cPass™ SARS-CoV-2 Neutralizing Antibody Testing Service in Singapore

GenScript Biotech Corporation Parkway Laboratories and the Diagnostics Development DxD Hub announced their collaboration to provide the cPass SARSCoV neutralizing antibody test in Singapore through Parkways panel of specialist and GP clinics

11

Apr 2021

Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

Cosmo Pharmaceuticals NV today announced the FDA approval of GI Genius intelligent endoscopy system its revolutionary device for lesion detection during colonoscopyThe GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than years of research and investments focused to gene...

09

Apr 2021

Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)

Aprea Therapeutics Inc a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p today announced that the US Food and Drug Administration FDA has granted Orphan Drug designation to eprenetapopt for treatment...

EventsRead more...

13 - 15

Apr 2021

15 - 16

Apr 2021

Euro Cardiology Summit 2021

Eliza George
Holiday Inn London - Heathrow M4

TOP ARTICLES

  • 5

    Personalised Therapy

    Drugs can be formulated in the form of tablets pellets emulsion cream and many others for patient consumption...

KNOWLEDGE BANK

  • Interviews

    Takeda Pharmaceutical Company Limited

    Chief Medical & Scientific Officer

    Scientific progress depends upon collaboration iPS cell technology is at the forefront of pharmaceutical innovation and Takeda strives to bring innovative treatments to patients Both Takeda and CiRA have the common goal of providing patients and healthcare professionals with innovative new treatments
  • Case Studies

    Viral Clearance For Biopharmaceutical Downstream Processes

    Abstract Viral clearance studies are mandated prior to entering clinical trials and for commercial launch of biopharmaceuticals These studies are a key component of risk mitigation to reduce the potential for iatrogenic transmission of pathogenic viruses This paper reviews regulatory guidance and practical strategies for designing viral clearance studies Ess

  • White Papers

    Pharmaceutical Serialization Track And Trace

    Summary Pharmaceutical companies have to contend with challenges stemming from supply chain security lapses testing in theft diversion and product recalls counterfeiting and stringent regulations In addition to alarming safety concerns these challenges also impair the health of the industry by adversely impacting profits brand credibility and research in

EDITORIAL SECTION

  • EXPERT Talk

    PHARMA LOGISTICS TRENDS

    Pharma logistics is undergoing profound change throughout Asia as the ageing population drives a growing need for new pharma solutions together with s...